Drug Patents owned by Seagen
1. Drug name - TUKYSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(2 years from now) | |
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(8 years from now) | |
| CN101356171A | SEAGEN | N4-Phenyl-Quinazoline-4-Amine Derivatives And Related Compounds As Erbbi Type Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases |
Jun, 2016
(6 years ago) | |
| CN102432552B | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN103772373B | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN103664802A | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN102432552A | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN103772373A | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN103664802B | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| CN102887891B | SEAGEN | N4-Phenyl-Quinazoline - -4 - Amine Derivatives And Related Compounds |
Nov, 2026
(4 years from now) | |
| CN102887891A | SEAGEN | N4-Phenyl - -4 - Amine Derivatives And Related Compounds |
Nov, 2026
(4 years from now) | |
| IN200600688P1 | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| IN245128B | SEAGEN | A Substituted Quinazoline Compound Including Resolved Enantiomers, Diastereomers, And Pharmaceutically Acceptable Salts Thereof |
Aug, 2024
(1 year, 10 months from now) | |
| IN200804058P1 | SEAGEN | Erbb Inhibitors |
Nov, 2026
(4 years from now) | |
| IN304285B | SEAGEN | Erbb Inhibitors |
Nov, 2026
(4 years from now) | |
| EP1660090B1 | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP1660090A4 | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP1660090A1 | SEAGEN | Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP2090575B1 | SEAGEN | Processes And Intermediates For The Preparation Of N4-Phenyl-Quinazoline-4-Amine Derivatives |
Nov, 2026
(4 years from now) | |
| EP2090575A1 | SEAGEN | Processes And Intermediates For The Preparation Of N4-Phenyl-Quinazoline-4-Amine Derivatives |
Nov, 2026
(4 years from now) | |
| EP1971601A2 | SEAGEN | N4-Phenyl-Quinazoline-4 -Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases |
Nov, 2026
(4 years from now) | |
| EP1971601B1 | SEAGEN | N4-Phenyl-Quinazoline-4 -Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases |
Nov, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(4 years from now) | |
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(10 years from now) | |
Drugs and Companies using TUCATINIB ingredient
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 150MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.